



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0


F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

OV808a : Peritoneum and omentum secondary tumor tissue array (all from ovary), including pathology grade, 40 cases/80 cores

Microarray Panel	Peritoneum and omentum secondary tumor tissue microarray, containing 39 adenocarcinoma, 1 urothelial carcinoma, duplicated cores per case	
Cores	80	OV808a H&E 
Cases	40	
Row number	8	
Column number	10	
Core Diameter (mm)	1.5	
Thickness (µm)	5	
Tissue Array Type	FFPE	
Species	Human	
Applications	Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page.	
Notes	1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours. In the following specsheet, "*" means invalid core; "-" means no applicable or negative in IHC markers.	

	1	2	3	4	5	6	7	8	9	10
A	Per	Per	Per	Per	Ome	Ome	Mes	Mes	Mes	Mes
B	Ome	Ome	Gre	Gre	Ome	Ome	Ome	Ome	Gre	Gre
C	Gre	Gre	Gre	Gre	Gre	Gre	Ome	Ome	Gre	Gre
D	Gre	Gre	Gre	Gre	Gre	Gre	Ome	Ome	Ome	Ome
E	Gre	Gre	Gre	Gre	Gre	Gre	Gre	Gre	Gre	Gre
F	Ome	Ome	Ome	Ome	Gre	Gre	Gre	Gre	Ome	Ome
G	Gre	Gre	Gre	Gre	Gre	Gre	Ome	Ome	Ome	Ome
H	Gre	Gre	Ome	Ome	Ome	Ome	Gre	Gre	Ome	Ome

Legend: Gre - Greater omentum, Mes - Mesentery, Ome - Omentum, Per - Peritoneum

● - Malignant tumor

, tissue IDs are available in exported Excel files.

Pos.	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	TNM	Grade	Stage	Type	Image
A1	1	47	F	Peritoneum	Adenocarcinoma, from ovary		3		Malignant	
A2	2	47	F	Peritoneum	Adenocarcinoma, from ovary		3		Malignant	
A3	3	49	F	Peritoneum	Adenocarcinoma, from ovary		3		Malignant	
A4	4	49	F	Peritoneum	Adenocarcinoma, from ovary		3		Malignant	
A5	5	40	F	Omentum	Papillary adenocarcinoma, from ovary		2		Malignant	
A6	6	40	F	Omentum	Papillary adenocarcinoma, from ovary		2		Malignant	
A7	7	47	F	Mesentery	Papillary adenocarcinoma, from ovary		2		Malignant	
A8	8	47	F	Mesentery	Papillary adenocarcinoma, from ovary		2		Malignant	
A9	9	59	F	Mesentery	Papillary adenocarcinoma, from ovary		2		Malignant	
A10	10	59	F	Mesentery	Papillary adenocarcinoma, from ovary		2		Malignant	
B1	11	59	F	Omentum	Papillary adenocarcinoma, from ovary		2		Malignant	
B2	12	59	F	Omentum	Papillary adenocarcinoma, from ovary		2		Malignant	
B3	13	28	F	Greater omentum	Papillary adenocarcinoma, from ovary		2		Malignant	
B4	14	28	F	Greater omentum	Papillary adenocarcinoma, from ovary		2		Malignant	

B5	15	45	F	Omentum	Papillary adenocarcinoma, from ovary	2	Malignant
B6	16	45	F	Omentum	Papillary adenocarcinoma, from ovary	2	Malignant
B7	17	65	F	Omentum	Papillary adenocarcinoma, from ovary	2	Malignant
B8	18	65	F	Omentum	Papillary adenocarcinoma, from ovary	2	Malignant
B9	19	57	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
B10	20	57	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
C1	21	47	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
C2	22	47	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
C3	23	56	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
C4	24	56	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
C5	25	64	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
C6	26	64	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
C7	27	64	F	Omentum	Papillary adenocarcinoma, from ovary	2	Malignant
C8	28	64	F	Omentum	Papillary adenocarcinoma, from ovary	2	Malignant
C9	29	58	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
C10	30	58	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
D1	31	48	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
D2	32	48	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
D3	33	52	F	Greater omentum	Adenocarcinoma, from ovary	2	Malignant
D4	34	52	F	Greater omentum	Adenocarcinoma, from ovary	2	Malignant
D5	35	43	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
D6	36	43	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
D7	37	42	F	Omentum	Papillary adenocarcinoma, from ovary	2	Malignant
D8	38	42	F	Omentum	Papillary adenocarcinoma, from ovary	2	Malignant
D9	39	63	F	Omentum	Papillary adenocarcinoma, from ovary	2	Malignant
D10	40	63	F	Omentum	Papillary adenocarcinoma, from ovary	2	Malignant
E1	41	50	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
E2	42	50	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
E3	43	50	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
E4	44	50	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
E5	45	62	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
E6	46	62	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
E7	47	52	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
E8	48	52	F	Greater omentum	Papillary adenocarcinoma, from ovary	2	Malignant
E9	49	37	F	Greater omentum	Adenocarcinoma, from ovary	3	Malignant
E10	50	37	F	Greater omentum	Adenocarcinoma, from ovary	3	Malignant
F1	51	49	F	Omentum	Adenocarcinoma, from ovary	3	Malignant
F2	52	49	F	Omentum	Adenocarcinoma, from ovary	3	Malignant
F3	53	49	F	Omentum	Adenocarcinoma, from ovary	3	Malignant
F4	54	49	F	Omentum	Adenocarcinoma, from ovary	3	Malignant
F5	55	64	F	Greater omentum	Adenocarcinoma, from ovary	3	Malignant
F6	56	64	F	Greater omentum	Adenocarcinoma, from ovary	3	Malignant
F7	57	52	F	Greater omentum	Adenocarcinoma, from ovary	3	Malignant
F8	58	52	F	Greater omentum	Adenocarcinoma, from ovary	3	Malignant
F9	59	57	F	Omentum	Adenocarcinoma, from ovary	3	Malignant
F10	60	57	F	Omentum	Adenocarcinoma, from ovary	3	Malignant
G1	61	45	F	Greater omentum	Adenocarcinoma, from ovary	3	Malignant
G2	62	45	F	Greater omentum	Adenocarcinoma, from ovary	3	Malignant
G3	63	47	F	Greater omentum	Adenocarcinoma, from ovary	3	Malignant
G4	64	47	F	Greater omentum	Adenocarcinoma, from ovary	3	Malignant
G5	65	41	F	Greater omentum	Adenocarcinoma, from ovary	3	Malignant
G6	66	41	F	Greater omentum	Adenocarcinoma, from ovary	3	Malignant
G7	67	56	F	Omentum	Adenocarcinoma, from ovary	3	Malignant
G8	68	56	F	Omentum	Adenocarcinoma, from ovary	3	Malignant
G9	69	45	F	Omentum	Adenocarcinoma, from ovary	3	Malignant
G10	70	45	F	Omentum	Adenocarcinoma, from ovary	3	Malignant
H1	71	48	F	Greater omentum	Adenocarcinoma, from ovary	3	Malignant
H2	72	48	F	Greater omentum	Adenocarcinoma, from ovary	3	Malignant
H3	73	55	F	Omentum	Adenocarcinoma, from ovary	3	Malignant
H4	74	55	F	Omentum	Adenocarcinoma, from ovary	3	Malignant

H5	75	62	F	Omentum	Adenocarcinoma, from ovary		3		Malignant	
H6	76	62	F	Omentum	Adenocarcinoma, from ovary		3		Malignant	
H7	77	50	F	Greater omentum	Adenocarcinoma, from ovary		3		Malignant	
H8	78	50	F	Greater omentum	Adenocarcinoma, from ovary		3		Malignant	
H9	79	58	F	Omentum	Urothelial carcinoma, from ovary		-		Malignant	
H10	80	58	F	Omentum	Urothelial carcinoma, from ovary		-		Malignant	
-	0	42	M	Adrenal gland	Pheochromocytoma (tissue marker)		-		Malignant	

AMSBIO | www.amsbio.com | info@amsbio.com

AMSBIO LLC
USA & Canada 
1035 Cambridge Street,
Cambridge, MA 02141
T: +1 (617) 945-5033 or
T: +1 (800) 987-0985
F: +1 (617) 945-8218

AMSBIO Europe BV
EU 
Berenkoog 41,
1822 BH Alkmaar,
Netherlands
T: +31 (0) 72 8080244
F: +31 (0) 72 8080142

AMS Biotechnology (Europe) Ltd
UK & Rest of the World 
184 Park Drive, Milton Park
Abingdon OX14 4SE
T: +44 (0) 1235 828 200
F: +44 (0) 1235 820 482

AMS Biotechnology (Europe) Ltd
Switzerland 
Via Lisano 3,
(CP.683)
CH-6900 Massagno
T: +41 (0) 91 604 55 22
F: +41 (0) 91 605 17 85

AMSBIO Europe BV
Deutschland 
T: +49 (0) 69 779099
F: +49 (0) 69 13376880